Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002033710 | SCV002270107 | uncertain significance | Senior-Loken syndrome 7; Bardet-Biedl syndrome 16 | 2022-11-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SDCCAG8 protein function. ClinVar contains an entry for this variant (Variation ID: 1488083). This variant has not been reported in the literature in individuals affected with SDCCAG8-related conditions. This variant is present in population databases (rs769004589, gnomAD 0.03%). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 278 of the SDCCAG8 protein (p.Arg278Cys). |
Fulgent Genetics, |
RCV002033710 | SCV002781878 | uncertain significance | Senior-Loken syndrome 7; Bardet-Biedl syndrome 16 | 2021-07-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003303581 | SCV003976788 | uncertain significance | Inborn genetic diseases | 2023-05-03 | criteria provided, single submitter | clinical testing | The c.832C>T (p.R278C) alteration is located in exon 8 (coding exon 8) of the SDCCAG8 gene. This alteration results from a C to T substitution at nucleotide position 832, causing the arginine (R) at amino acid position 278 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |